Mr. Bill Jackson reports

VECTOR SCIENCE & THERAPEUTICS EXPANDS BOARD OF DIRECTORS WITH APPOINTMENT OF DR. ALEXANDER DOBRANOWSKI AND SCOTT KELLY

Vector Science and Therapeutics Corp. has appointed Dr. Alexander Dobranowski and Scott Kelly to its board of directors, further strengthening the company's governance and strategic capabilities as it advances toward commercialization of its biomechanical drug delivery platforms.

Key highlights:

• Dr. Dobranowski, president, director and co-founder of Healwell AI, brings health care AI (artificial intelligence) and clinical leadership to the Vector board;
• Mr. Kelly, a proven C-level leader with 22-plus years of capital markets experience, strengthens Vector's governance as a newly listed TSX Venture Exchange company;
• Strategic timing: appointments come as Vector advances toward commercialization of its biomechanical drug delivery platforms;
• Expanded board now includes chairman Tommy Thompson, chief executive officer Bill Jackson, co-founder and chief commercial officer Barry Hix, and the two new appointees.

Dr. Dobranowski is president, director and co-founder of Healwell AI, a leading health care artificial intelligence company focused on preventative care. With more than 15 years of clinical and health care technology experience, Dr. Dobranowski has led multiple ventures in the development and execution of innovative AI-driven solutions to complex health care challenges. His expertise at the intersection of clinical medicine and health technology brings a critical dimension to Vector's board as the company builds its data and outcomes infrastructure.

"Precision delivery of peptides and biologics represents one of the most consequential frontiers in modern therapeutics," said Dr. Dobranowski. "The ability to steer therapeutic agents to a targeted site with consistency and control is transformational. I look forward to contributing to the clinical and commercial strategy as Vector brings its important technologies to physicians and patients."

Mr. Kelly brings more than 22 years of capital markets experience to the board, with an extensive record as a director and chief financial officer of public companies listed on the TSX Venture Exchange and the Canadian Securities Exchange. Mr. Kelly holds a bachelor of commerce from Royal Roads University. His familiarity with public company governance and capital markets operations strengthens Vector's foundation as a newly listed TSX-V company.

"Vector Science is at an exciting inflection point as a newly listed company with a differentiated technology platform and a clear path to commercialization," said Mr. Kelly. "I look forward to putting my capital markets experience to work as the company builds its investor base and executes on its growth strategy."

Dr. Dobranowski and Mr. Kelly join a board that includes Mr. Hix, Mr. Thompson, former Wisconsin Governor and U.S. Secretary of Health and Human Services, who serves as chairman, and Mr. Jackson.

"These appointments reflect the momentum we are building at Vector," said Mr. Jackson. "With Dr. Dobranowski's clinical and health care AI leadership and Mr. Kelly's capital markets expertise now on our Board, Vector is exceptionally well positioned to execute on our commercialization strategy and deliver on the promise of our biomechanical drug delivery platforms."

About Vector Science and Therapeutics Corp.

Vector Science, headquartered in Mequon, Wis., develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risks are unacceptable. The company's shares are listed on the TSX Venture Exchange under the symbol PAIN.

We seek Safe Harbor.